MeiraGTx's Strong Q2
MeiraGTx Reports Robust Q2 Revenue and Net Income, Bolstered by Key Strategic Moves
Key Points
In Q2 2026 MeiraGTx's revenue mix included substantial related-party contributions: $104.9 million in related-party service revenue and $204.6 million in related-party license revenue, alongside $11.9 million in standard service revenue.
MeiraGTx completed the acquisition of all interests and rights to botareti (bota-vec rights) from Johnson & Johnson for a $25 million upfront payment and expects global regulatory filings for the XLRP therapy in 2026.
The pivotal AQUAx2 Phase 2 trial of AAV2-hAQP1 has completed enrollment, with a 12-month data readout targeted for the second quarter of 2027.
Insider activity shows notable selling by senior management over the past six months: CFO & COO Richard Giroux sold 112,000 shares (~$1.27 million), President & CEO Alexandria Forbes sold 124,000 shares (~$1.03 million), and Chief Science Officer Stuart Naylor sold 55,320 shares (~$668,377).
MeiraGTx's cash, cash equivalents and restricted cash totaled $145.4 million at June 30, 2026, up from $34.4 million a year earlier, underscoring a stronger liquidity position.
MeiraGTx Holdings posted a blockbuster second quarter, reporting $321.4 million in revenue and $160.7 million in net income for Q2 2026, according to Quiver Quantitative. That compares to a net loss just a year earlier, marking a dramatic swing in financial performance for the gene therapy company.
The results crushed Wall Street expectations. Yahoo Finance noted MeiraGTx beat the Zacks Consensus Estimate of $1.71 per share by a staggering 538.46%, compared to a loss of $0.39 per share in the same quarter last year.
Revenue Fueled by Massive Johnson & Johnson Deal
The headline numbers tell only part of the story. The vast majority of MeiraGTx's revenue came from related-party transactions, according to Goldea Capital. Of the $321.4 million total, $204.6 million came from related-party license revenue and $104.9 million from related-party service revenue. Only $11.9 million was standard service revenue.
MeiraGTx also completed its acquisition of all rights to botareti, a gene therapy for an inherited eye disease called XLRP, from Johnson & Johnson. The company paid $25 million upfront for the deal. It now expects to file for global regulatory approval of botareti before the end of 2026, per Quartr.
FDA Breakthrough Tag Boosts Eye Therapy Pipeline
MeiraGTx scored a major regulatory win this quarter. The FDA granted Breakthrough Therapy Designation to AAV2-hAQP1, a gene therapy designed to treat radiation-induced dry mouth, known as xerostomia. This designation can speed up the development and review process, according to Quiver Quantitative.
The pivotal AQUAx2 Phase 2 trial of AAV2-hAQP1 has finished enrolling patients. A 12-month data readout is targeted for the second quarter of 2027, per Quartr. Strong 3-year Phase 1 data for the same therapy has already been reported, adding confidence ahead of that milestone.
Cash Nearly Quadrupled, Oberland Deal Adds $400M Firepower
MeiraGTx's balance sheet strengthened sharply. The company held $145.4 million in cash, cash equivalents, and restricted cash as of June 30, 2026. That is up from just $34.4 million a year earlier — a near quadrupling in liquidity, according to Goldea Capital.
To extend its financial runway further, MeiraGTx signed a deal with Oberland Capital for up to $400 million in investment. The agreement gives the company significant resources to fund its growing pipeline of genetic medicines, per Yahoo Finance.
Insiders Selling While Analysts Stay Bullish
Despite strong results, senior insiders have been trimming their holdings. Over the past six months, CEO Alexandria Forbes sold 124,000 shares worth roughly $1.03 million. CFO and COO Richard Giroux sold 112,000 shares for about $1.27 million. Chief Science Officer Stuart Naylor sold 55,320 shares for approximately $668,377, according to Quiver Quantitative.
Wall Street is not spooked. Eight analysts covering MeiraGTx currently rate it a Moderate Buy, with multiple price-target upgrades following the quarterly report. Institutional investors have continued adding to their positions, signaling broader market confidence in the company's pipeline and growth trajectory, per Yahoo Finance.
Sentiment
Mostly PositivePublishers
11
Articles
7
Reach
18
